Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Do you utilize consolidative radiation for metastatic NSCLC lung cancer patients on maintenance immunotherapy?
Or do you reserve in case of oligo-progression or progressive/symptomatic disease?
Answer from: Medical Oncologist at Community Practice
Yes but please refer these patients for NRG-LU002 study which is directly addressing this important question.
Sign in or Register to read more
5515
Related Questions
In a patient with node-positive limited-stage small cell lung cancer, how do you approach radiation in a patient whose small primary tumor resolves after one cycle of chemotherapy?
Would a BRAF V600E mutation affect your decision to give adjuvant therapy in a patient with lung cancer?
Is there a role for nintedanib in the management of patients with radiation-induced pulmonary fibrosis?
Under what circumstances, if any, would you wait on initiating a TKI for metastatic recurrence of a Stage III NSCLC which occurred while on consolidative durvalumab to minimize pneumonitis risk?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
How do you transition between TKIs for stage IV NSCLC with actionable mutations?
Would you offer immunotherapy to a patient with stage II NSCLC with an EGFR exon 20 mutation?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
Do you offer adjuvant durvalumab for stage I small cell lung cancer following SBRT or surgery?